Does IVX have anything to offer in the treatent of drug resistant candida auris? Fear growing in US and seeing antifungal medical stocks in US taking some big leaps from this space in recent days (Scynexis up 74% 2 days).
The Invion 26 October 2022 announcement noted Photosoft had some success against drug resistant fungal infections. Hoping perhaps there can be some discussion about possible potential for this stock in what is becoming a rapidly growing concern in the world, as well as all the well discussed negatives which have overpopulated many HC forums. Whilst like many of you I invest to make a return I also invest in diversified number of stocks that may add benfit to the world and to us all. All the best to everyone in difficult times.
IVX Price at posting:
0.8¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)